Rhythm Pharmaceuticals (RYTM) Cash from Operations (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Cash from Operations data on file, last reported at 44185000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 9.5% year-over-year to 44185000.0 in Q1 2026; TTM through Mar 2026 was 119509000.0, a 5.31% decrease from a year earlier, with the FY2025 full-year figure at 115675000.0, down 1.58% from the prior year.
• Cash from Operations for Q1 2026 stood at 44185000.0, down from 25389000.0 in the prior quarter.
• Over the last five years, Cash from Operations for RYTM reached as high as 18845000.0 in Q4 2024 and fell as low as 53632000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 34313176.47 across 5 years, with a median of 34000000.0 in 2022.
• Across the five-year window, Cash from Operations sank 59.95% in 2022 and soared 37.75% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 34000000.0 in 2022, then grew by 13.58% to 29383000.0 in 2023, then surged by 35.86% to 18845000.0 in 2024, then plunged by 34.73% to 25389000.0 in 2025, then slumped by 74.03% to 44185000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 44185000.0 in Q1 2026, 25389000.0 in Q4 2025, and 26622000.0 in Q3 2025.